Depression - Pipeline Review, H1 2014: 55 Companies and 96 Drugs Profiled
M2 - Thu May 08, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2szh97/depression) has announced the addition of the "Depression - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AB Science - Acetylon Pharmaceuticals, Inc. - Ache Laboratorios Farmaceuticos S/A - Acino Pharma AG - Addex Therapeutics - Affectis Pharmaceuticals AG - Allergan, Inc. - Anavex Life Sciences Corp. - Angelini Group - Angita B.V. - Aphios Corporation - AstraZeneca PLC - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - BioCrea GmbH - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Clera Inc. - Concert Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dart NeuroScience LLC - Domain Therapeutics SA - Eisai Co., Ltd. - Eli Lilly and Company - FAES Farma SA - Heptares Therapeutics Ltd. - Hydra Biosciences, Inc. - Impax Laboratories, Inc. - Indus Biotech Private Limited - Intra-Cellular Therapies, Inc. and many more Drug Profiles: - trazodone hydrochloride - quetiapine fumarate ER - Triple Reuptake Inhibitors - verucerfont - masitinib - nefiracetam - epoetin alfa - PH-10-A - CLR-3001 - Neurokinin-1 Receptor Antagonists For Depression - progesterone - SRX-251 - SRX-246 - ITI-007 - RGH-618 - fludrocortisone - BLI-1005 - WF-516 - Projectx-1120 - TS-111 - IPX-237 - SPN-809 - ANAVEX-1-41 - F-98214-TA - Xantol - E-2508 - NNI-351 - INDUS-860 - NW-3509 - SKL-PSY and many more For more information visit http://www.researchandmarkets.com/research/2szh97/depression
Cognitive Impairment - Pipeline Review, H1 2014: 40 Companies and 82 Drugs Profiled
M2 - Thu May 08, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kz65z/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AGY Therapeutics, Inc. - AbbVie Inc. - Amarantus Bioscience Holdings, Inc. - Avineuro Pharmaceuticals, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celon Pharma Sp. z o.o. - CoMentis, Inc. - D-Pharm Ltd. - Dart NeuroScience LLC - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Intra-Cellular Therapies, Inc. - Merck & Co., Inc. - Merz Pharmaceuticals GmbH - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeuroDerm Ltd. - Novartis AG - Octapharma AG - Omeros Corporation - Pacific Northwest Biotechnology, LLC - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - QR Pharma, Inc. - SK Biopharmaceuticals Co., Ltd. Drug Profiles: - MK-8931 - idursulfase - AQW-051 - GTS-21 - AVN-211 - tesamorelin acetate - eltoprazine - CHF-5074 - immune globulin (human) - ABT-126 - Peptide T - citicoline sodium - erteberel - ladostigil tartrate - sodium oligomannurarate - DAOI-B - levetiracetam - mifepristone - F-03 - Posiphen - GSK-933776 - roflumilast - ABT-560 - TTP-4000 - ITI-214 - HTL-9936 - SKL-15508 - BMS-933043 - AN-761 - PH-15 For more information visit http://www.researchandmarkets.com/research/4kz65z/cognitive
Intra-Cellular Therapies Presents New Data From the Phase 2 Clinical Trial of ITI-007 in Schizophrenia at the 167th Annual Meeting of the American Psychiatric Association
GlobeNewswire - Tue May 06, 1:30PM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders is presenting additional data from the Phase 2 clinical trial of ITI-007 in schizophrenia at the 167th Annual Meeting of the American Psychiatric Association (APA) being held in New York, NY.
Intra-Cellular Therapies Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 05, 3:01PM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2014, and provided a corporate update.
Intra-Cellular Therapies to Present at the Deutsche Bank 39th Annual Health Care Conference
GlobeNewswire - Thu May 01, 7:31AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will present at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014, at 1:30 P.M. Eastern Time in Boston, MA. Dr. Mates will provide a corporate overview and business update.